Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928771 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,681
- Enrollment target
NCT01928771 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,681 participants.
The verdict
NCT01928771, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,681 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,681 participants |
| Start Date | 2013-09-19 |
| Est. Completion | 2016-04-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928771
The ClinicalTrials.gov registry entry for NCT01928771 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,681 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01928771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01928771 about?
NCT01928771 is a clinical study titled "Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma". The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
What is the current status of trial NCT01928771?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,681 participants. The study started on 2013-09-19. Estimated completion is 2016-04-05.
What interventions are being tested in trial NCT01928771?
The interventions under investigation include: Placebo (BIOLOGICAL), Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01928771?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.